DXR vs. CLPT, TELA, QIPT, BWAY, SSKN, KRMD, BLUA, SRTS, HSAQ, and MGRM
Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include ClearPoint Neuro (CLPT), TELA Bio (TELA), Quipt Home Medical (QIPT), BrainsWay (BWAY), STRATA Skin Sciences (SSKN), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), and Monogram Orthopaedics (MGRM). These companies are all part of the "surgical & medical instruments" industry.
Daxor (NASDAQ:DXR) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
ClearPoint Neuro received 20 more outperform votes than Daxor when rated by MarketBeat users.
In the previous week, ClearPoint Neuro had 3 more articles in the media than Daxor. MarketBeat recorded 3 mentions for ClearPoint Neuro and 0 mentions for Daxor. ClearPoint Neuro's average media sentiment score of 1.19 beat Daxor's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the news media.
1.3% of Daxor shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 60.6% of Daxor shares are owned by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ClearPoint Neuro has a consensus target price of $12.00, indicating a potential upside of 113.52%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Daxor.
Daxor has higher earnings, but lower revenue than ClearPoint Neuro.
Daxor has a beta of -0.55, suggesting that its stock price is 155% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
Daxor has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -78.84%. Daxor's return on equity of 0.00% beat ClearPoint Neuro's return on equity.
Summary
ClearPoint Neuro beats Daxor on 8 of the 12 factors compared between the two stocks.
Get Daxor News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
